MOUNTAIN VIEW, Calif. — June 6, 2012 — Based on its recent analysis of the organ-specific
molecular imaging market, Frost & Sullivan recognizes Naviscan Inc. (Naviscan) with the 2012
European Frost & Sullivan Award for Product Quality Leadership for its organ-specific PET
scanner. With its main application in Positron Emission Mammography (PEM), the product offers
multiple benefits to the customer over competing products.
Naviscan’s PET scanner offers numerous advantages in a wide variety of clinical applications,
such as detection, staging, monitoring response to neo-adjuvant chemotherapy and re-staging of
breast cancer, detection of peripheral tumors, and screening for recurrent melanoma.
Applications that are showing promise in ongoing clinical trials include osteoarthritis and
rheumatoid arthritis. With its ability to position the detectors in close proximity to the organ
imaged—achieving higher resolution than a whole-body (WB) PET scanner—the product is
simply superior in quality.
Naviscan’s intelligent design, including advanced photonics, biopsy guidance software and
cutting-edge visualization software, MIMViewer TM PEM workstation, which was developed by
MIMvista Software™, helps deliver high-quality 3D tomographic images with excellent spatial
resolution. While the existing conventional screening methods for breast cancer produce results
of 80 to 91 percent sensitivity, PEM offers 93 percent sensitivity and 93 percent specificity. The
visualization software is characteristic of its user-friendly interface with options for creating
customized images with attention to regions of interest that can be saved as DICOM files to any
“The proven accuracy, high sensitivity and specificity of the scanner in the detection of lesions,
particularly for breast cancer, helps the physicians make confident and informed diagnosis,” said
Frost & Sullivan Research Analyst Kaavya Karunanithi. “This helps in eliminating the number of
false positives that lead to unnecessary biopsies.”
Further, the compact nature of the product offers additional economic benefits by reducing
maintenance and installation charges when compared to WB PET or MRI scanners. Naviscan’s
design team has made the PET scanner very portable to enable remote diagnostics.
“The company’s major focus on quality in the past five years has enabled its PET scanner to
achieve high market penetration in the USA by capitalizing on numerous peer-reviewed
publications from multicenter prospective clinical trials that showcase the high sensitivity,
specificity and accuracy that the product delivers,” notes Karunanithi. “It is with this reputation that
the product aims to capture the European market.”
The product is endorsed by the FDA and has a CE mark for its high-quality compliance, so it is
certain to achieve the market leadership position in organ-specific molecular imaging in Europe in
the near future. Naviscan introduced initial installations in Turkey and Germany in 2011. There
are also orders for installations in Spain and Switzerland, and a strong pipeline of opportunities
across Europe for 2012.
Overall, Naviscan’s organ-specific PET scanner, due to its high sensitivity, high specificity and
accuracy, complements conventional imaging methods, such as mammography or ultrasound,
and is a research-proven alternative to MRI. In recognition, Frost & Sullivan is proud to present Naviscan with the 2012 European Frost & Sullivan Award for Product Quality Leadership in the
organ-specific molecular imaging market.
Each year, Frost & Sullivan presents this award to the company that has demonstrated
outstanding product performance and value to customers. The award recognizes significant
contribution in terms of design, usability and reliability.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global
markets for demonstrating outstanding achievement and superior performance in areas such as
leadership, technological innovation, customer service, and strategic product development.
Industry analysts compare market participants and measure performance through in-depth
interviews, analysis, and extensive secondary research in order to identify best practices in the
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners
intended to provide organ-specific molecular imaging and guide radiological and surgical
procedures. The Naviscan PET scanner is currently installed and available in breast and imaging
centers throughout the world. and has global distribution in 34 countries. The Company is
headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a
high-resolution PET scanner designed to image small body parts and for breast biopsy image
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage
visionary innovation that addresses the global challenges and related growth opportunities that
will make or break today's market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating
two key elements driving visionary innovation: The Integrated Value Proposition and The
• The Integrated Value Proposition provides support to our clients throughout all phases of
their journey to visionary innovation, including: research, analysis, strategy, vision, innovation
• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which
visionary innovation becomes possible. This includes our 360 degree research,
comprehensive industry coverage, career best practices as well as our global footprint of
more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000,
emerging businesses, the public sector and the investment community. Is your organization
prepared for the next profound wave of industry convergence, disruptive technologies, increasing
competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics
and emerging economies?
P: 210. 247.3870